logo
Has Kris Jenner found the fountain of youth? Experts weigh in on her stunning transformation

Has Kris Jenner found the fountain of youth? Experts weigh in on her stunning transformation

Fox News4 hours ago

Kris Jenner — known as the "momager" of the Kardashian-Jenner empire — has made headlines in recent weeks for her more youthful appearance, sparking rumors of a possible deep plane facelift.
A representative for Jenner confirmed to another outlet that Dr. Steven Levine of New York City performed Jenner's recent work, but did not specify the type of procedure. (Fox News Digital reached out to Levine and Jenner for comment.)
Dr. Patrick Davis, a Beverly Hills facial plastic surgeon, said that Jenner appears "youthful and natural," which is the hallmark of a "well-performed procedure."
"It is difficult to comment specifically on what technique was performed, though in some fashion, the structural elements of her face were lifted to reset her skin tissues," Davis, who has not treated Jenner, hypothesized in an interview with Fox News Digital.
"She has a healthy-looking distribution of fat contributing to this new look, which could potentially be the effect of a fat transfer in addition to a facelift."
Dr. Jonathan Kaplan, a board-certified plastic surgeon with Pacific Heights Plastic Surgery in San Francisco, agreed that Jenner has gotten an "incredible result" from what "appears to be" a deep plane facelift.
With a standard or traditional facelift — also known as a SMAS facelift, or a Superficial Musculoaponeurotic System facelift — the surgeon makes incisions behind the hairline and around the front of the ear, lifting and tightening the deeper tissues and muscles and then removing excess skin.
This can eliminate wrinkles, sagging skin and the "jowl-like" effect, achieving a more youthful contour of the face and neck, according to the American Board of Cosmetic Surgery.
Davis said most of his education and training has focused on deep plane facelifts.
"A deep plane facelift involves a wider dissection under the structural elements of the face, which then allows the surgeon to reset a greater proportion of facial tissues," Davis said.
"The benefit of this technique is that a more natural, vertical reset can be achieved — and more importantly, the tissues re-attach themselves in a broader way, allowing for a more durable result."
It's important to choose a facelift that is right for the patient and that falls within the surgeon's expertise, Davis noted.
"In those patients who have had multiple facelifts in the past, it could be wise to perform a simpler SMAS facelift with less dissection, as the tissues have been manipulated in the past," he advised.
Any elective or non-elective surgery carries some degree of risk, experts agree.
"In any given surgery, there is a risk of infection, nerve damage, or bruising and swelling," Davis cautioned. "These are minimized based on the surgeon's experience and the frequency with which they perform the procedure."
It is important that the surgeon goes over these risks with the patient in person, according to Davis.
Because the deep plane technique involves a more extensive dissection of tissues under and around facial nerves, Kaplan cautioned that the biggest risk is facial paralysis, which can be temporary or permanent.
"It's a newer variation that requires a greater understanding of the anatomy to be successful," he said.
Davis tells his patients that a deep plane facelift has a typical recovery time of about six months for full results, though many can return to work and other functions within three to four weeks.
"These procedures are not debilitating — however, there is some cosmetic downtime, which varies from patient to patient," he noted.
In Kaplan's practice, he encourages most patients to be out and about two weeks after surgery.
"They may still have some bruising, but it's typically in the lower neck or upper chest at that point and can be covered," he said.
Various factors can affect a patient's recovery timeline, the experts say. Some, like genetics, can't be controlled.
"Other things, however — like a low-salt diet, exercise, lymphatic massage, hyperbaric oxygen treatments and keeping up with proper post-op care — are within our control," Davis said.
Most surgeons will have the patient wear a head and neck compression garment for two weeks, Kaplan noted.
"In general, the patient should not be in a great deal of pain — if they are, that can actually be a sign of a hematoma (bleeding under the skin)," he said.
When opting for a facelift, it's important to choose a board-certified facial plastic surgeon who is specifically trained in facelifts of deep SMAS tissue, doctors agreed.
Before undergoing a facelift, Davis emphasized the need for the patient to share as much detail as possible about his or her medical history, lifestyle and aesthetic goals.
"When we have consultations with prospective clients, we want to know more about their diet, lifestyle, support system and any health conditions that may affect a surgery," he said.
Kaplan noted that it's important to tell the surgeon if you're taking any GLP-1 weight-loss medications, as they may ask you to pause them a week prior to surgery.
The most important things to ask a prospective surgeon, according to Davis, are where they put their incisions, how they close their incisions, details about their individual technique, and any information that provides better insight into their background, experience and frequency with which they perform that specific procedure.
For more Health articles, visit www.foxnews.com/health
"You want to find a surgeon who has extensive knowledge in facial plastic surgery and can provide their patients with tidy incisions that are well-hidden," he advised.
"Most of all, it is important that you are comfortable with your surgeon, as they will not only be with you for the procedure, but will be by your side on the recovery journey."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

After her heart started to fail, a first-of-its-kind surgery saved her life
After her heart started to fail, a first-of-its-kind surgery saved her life

CBS News

timean hour ago

  • CBS News

After her heart started to fail, a first-of-its-kind surgery saved her life

Sue Baker was used to spending time in the hospital. She had started having heart troubles in 2015, and as the issue escalated, she spent more and more time in the hospital. She had a pacemaker implanted to keep her heart beating. Once, she spent five days in a coma. In 2019, as her heart function continued to fail, Baker received a left ventricular assist device, or LVAD, a mechanical pump that helps the heart's left ventricle circulate blood throughout the body. For years, Baker lived on "batteries and electricity," but she didn't stop living her life. She married a man she loved, and they started building a life together in southeast Georgia. However, she knew the LVAD was only a stopgap measure, and wanted to make sure she was living a full life before her health declined further. Four years after getting the LVAD, Baker started having dangerous heart rhythms. She was admitted to the Mayo Clinic in Jacksonville, Florida, and was added to the transplant list to await a new heart. For months, the 58-year-old waited, often receiving painful shocks from her LVAD and pacemaker as they tried to keep her heart functioning. Her body was also producing too many antibodies, which put her at high risk for rejecting any organs she received. Her transplant cardiologist, Dr. Pareg Patel, tested multiple medications, including chemotherapies, to reduce the antibodies. The process was "very scary," she said. One day, Patel came to her with another option: She could have a liver transplant, in addition to the new heart. It might solve the antibody problem. There was just one catch: A heart-liver transplant had never been done in someone with an LVAD before. Her other option was palliative care. "We got to talking about it, and I was like 'You're not going to know unless somebody agrees to do this. There's not much choice, really,'" Baker recalled. "It was going to be an experiment one way or the other." Sue Baker in the hospital with her caretaker, Charlene. Sue Baker A first-of-its-kind transplant The liver is "like sponges that take down these antibodies," Patel explained. Sometimes, livers are transplanted alongside hearts to lower the risk of rejection. But the procedure means a patient needs to wait until a heart and liver are available from the same donor. Some people die on the waiting list, Patel said. But for Baker, it was the best option. "It's a story where we were able to find an out-of-the-box solution for somebody who I can guarantee you two years ago we would have said no to and put them in hospice," Patel said. "She had less than probably six months to live in, more likely three months." Baker spent months in the hospital, continuing to receive painful shocks from her LVAD and pacemaker. She had other complications, including diagnoses of COVID-19 and pneumonia. In September 2024, she finally received word that a heart and liver were available to her. Sue Baker in the hospital on her birthday. Sue Baker "I was shocked," Baker said. "I was so excited." Patel said he and his team anticipated that the surgery would be "challenging" and "very high risk" because of Baker's health complications but everyone believed it was the best possible option. Baker would also be donating her "perfectly healthy" liver to another patient, Patel said, in what's known as a domino operation. "I think the cool part of this is for Sue, is that by using this technology, number one, we were able to prove that by placing a liver and a heart from somebody is we're able to make antibodies go close to zero," Patel explained. "And number two, we were able to have Sue become not only a recipient of two organs, but also a donor in the same day." Blazing a path for other patients After her surgery, Baker said she had a long recovery, but spent her time in the hospital bonding with other patients. She tried to be a voice of optimism for other people waiting for transplants, she said. She also received a letter from the person who received her liver. After Baker recovered and left the hospital in October 2024, she was eager to resume her life in Georgia, but tragedy struck: Her husband died from a sudden cardiac arrest just weeks later. Burdened by medical bills and funeral expenses, her financial situation spiraled. She said her housing is now unstable, and most spare money goes to flying to regular check-ups at the Mayo Clinic. A GoFundMe has only raised a few hundred dollars. Patel said Baker will need frequent check-ups and medication to maintain her new organs. Mayo Clinic said it offers financial assistance and payment plan options, as well as financial counseling to patients who are uninsured or underinsured. Sue Baker and her care team. (L-R) - Dr. Daniel Yip, Dr. Juan Carlos Leoni Moreno, Sue Baker, Dr. Parag Patel, Dr. Rohan Goswami. Mayo Clinic Baker said she is leaning on her church for emotional support and other aid. She has a caretaker, Charlene, who helps with day-to-day life. She also hopes that her taking part in the first-of-its-kind surgery will allow more people to receive lifesaving treatment, and said the thought brings her some solace. Patel said that another surgery like Baker's was already conducted, and that another is in the works. "If it weren't for her, these other two patients would have no opportunity," Patel said. "Doing what I did, it opened it up for so many more patients," Baker said. "It made me very happy to know that more LVAD patients will be able to go through this and actually have a long chance at life."

A longer ‘winter': Public funding slowdown heightens pressure on biotech startups
A longer ‘winter': Public funding slowdown heightens pressure on biotech startups

Yahoo

timean hour ago

  • Yahoo

A longer ‘winter': Public funding slowdown heightens pressure on biotech startups

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology industry watchers were hopeful at the start of 2025. Venture funding appeared to be rebounding after a lengthy slump, and a smattering of new stock offerings and company acquisitions brewed optimism that the public markets might be similarly warming up to young drugmakers. But the positivity quickly dissipated. Trump administration policies gutted scientific research funding and raised questions about U.S. drug prices. Large layoffs and upheaval at public health agencies created regulatory turmoil that added risk to what's already, by its nature, a risky sector to invest in. The results were laid out in a June report from David Windley and Tucker Remmers, two analysts at the investment bank Jefferies. According to that report, funding in public biotech companies — be it from initial public offerings, follow-on stock offerings, or 'PIPE' deals — plummeted in May. The 'political and economic uncertainties' have "cast a cloud over biotech investment,' they wrote. 'Since product development cycles can range 12-15 years in this industry, biotechs (and their boards and investors) want clarity on FDA regulation, drug pricing, and funding before committing to large, [long-term] investments,' Windley and Remmers wrote. Investors and industry insiders interviewed by BioPharma Dive say that the public slowdown is trickling down to startups that have already been under intense pressure during a prolonged pullback. Companies and investors are struggling to align on valuations, making funding rounds more difficult to close than in prior years. The uphill battle in the public markets is further delaying IPO plans, too. "People are waiting to see what happens, and it's extended that winter," said Tim Scott, the president of Biocom California, an industry trade group. To date, only seven biotech companies have priced IPOs in 2025, and no large offerings have occurred since mid-February. No biotechs have publicly disclosed IPO ambitions in several months either, and one of the last to do so, Odyssey Therapeutics, pulled its offering in May. In a letter to the Securities and Exchange Commission, CEO Gary Glick wrote that it was 'not in the best interests of the company' to go public at that time. One reason IPOs have ground to a halt, experts say, is that the public markets aren't rewarding drug startups as predictably as they once were. Typically, drug companies can expect their value to climb after delivering positive clinical results. But 'even companies with good data aren't seeing a lot of movement in the public markets,' said Jonathan Norris, a managing director at HSBC Innovation Banking. As a result, Norris said, companies are looking at the time and expense it takes in the monthslong process to go public and wondering: 'What's the benefit?' 'If you have any readouts that are even eye squinting, you're going to get crushed,' he said. 'It's a tough, tough endeavor.' The shuttered IPO window is exacerbating problems for young biotechs. "If you don't have a public market opportunity, then the companies that are private have to think about ways to raise capital and stay private for longer," said Maina Bhaman, a partner at Sofinnova Partners. Feeling that burden, venture investors are becoming more conservative. While private funding hasn't plummeted as much as its public counterpart, investors are more selective and slower-moving. Funding has become increasingly consolidated into fewer and larger 'megarounds,' to the extent that more firms are compiling similar portfolios. And they're hard to finalize, even when most of a funding syndicate is already onboard, according to Norris. "People are struggling to figure out where the bottom of the market is and what's the appropriate valuation and expectation for that investment,' he said. "A lot of VCs are pencils down right now on deals they would otherwise be moving forward on,' Scott added. Pullbacks are nothing new in biotech. But what has been unusual, some say, is how long the sector has spent in the doldrums after peaking in early 2021. One reason is the most recent boom flooded the market with more companies than it could support. But another is that the ensuing correction has intensified amid regulatory and political upheaval. A report last week from Roel van den Akker, PwC's U.S. pharma and life science deals leader, predicted that companies will be 'preparing contingency plans' to account for delays in 'trial oversight' and drug applications. Drug companies are used to dealing with a high level of risk, as most experimental medicines never make it to market. But 'now you've got a lot more macro uncertainty that is being layered on top," Bhaman said. On the public side, that uncertainty has resulted in less patient investors, some of whom are pressing company boards to shut down after setbacks rather than change course. But some startups are taking drastic steps, too, such as cutting programs and staff to, some experts believe, depress their value so they can still attract investment. The "lack of surety" is pressuring biotechs to be as efficient as possible with their cash, Scott said, perhaps working on one program instead of a few. There have been multiple high-profile examples of late. Eikon Therapeutics and Insitro, two well-funded startups, both cited a need for 'prudence' in laying off staff. Norris expects more companies to proactively cut staff, or even close, as the longer-than-expected winter drags on. 'Most of those companies are not going to find the investors that they're hoping for,' he said. 'And I think that's just the unfortunate truth.' Recommended Reading Radiopharmaceutical drugmaker RayzeBio signals plans to go public

Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?

Yahoo

timean hour ago

  • Yahoo

Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?

Medical Properties Trust has a 7.2% yield and a history of dividend cuts behind it. Other healthcare REITs have high yields and dividends that have withstood adversity much better. Omega Healthcare has a 7.4% yield, and LTC Properties has a 6.5% yield. 10 stocks we like better than Medical Properties Trust › Medical Properties Trust (NYSE: MPW) has a lofty 7.2% yield. That compares to the S&P 500 index's skinny little 1.2% yield, and the average real estate investment trust's (REIT's) yield of around 4.1%. On the surface, it appears to be an obvious choice. But don't jump at the chance to buy Medical Properties Trust just yet. You can get similarly large yields from healthcare REIT peers Omega Healthcare (NYSE: OHI) and LTC Properties (NYSE: LTC), and both offer a more compelling dividend story than Medical Properties. Here's what you need to know. Take a look at the chart below for Medical Properties Trust. The orange line is the quarterly dividend, and the purple line is the stock price. Notice the massive drop in both that has occurred since 2022. That was when some of the REIT's large tenants started to experience financial troubles. It was the start of a tense and complicated period when a small number of Medical Properties Trust's tenants failed, and it had no choice but to cut its dividend. For long-term dividend investors, the lofty 7.2% yield on offer from Medical Properties Trust comes with some lofty risks. It's possible that the bad news is all out, and the REIT can start to turn its business around. However, that's far from a certainty. Unless you're willing to bet that the future will look much brighter from here, most dividend investors will probably want to tread with caution. In fact, even if a turnaround is underway, it's likely to be a years-long process. There's a contrast to be made here with healthcare REITs Omega Healthcare and LTC Properties. Both of these REITs focus on senior housing, including nursing homes and assisted living facilities. During the coronavirus pandemic's height, both of these property types were hard hit. The reason was pretty simple: COVID-19 is particularly deadly for unvaccinated older adults and spreads easily in group settings. Occupancy fell for both REITs, and there was a drought of new customers. Both Omega and LTC also had to deal with tenant problems, as some of their lessees had trouble paying rent. That would seem like a perfect storm that would lead to a dividend cut. Yet neither Omega nor LTC cut their dividends. To be fair, neither of these REITs has increased their dividends in years. But a static dividend is much better than a dividend cut. Right now, Omega's yield is 7.4%, while more diversified LTC Properties has a 6.5% yield. The future is starting to look brighter for each of these healthcare REITs. Omega's adjusted funds from operations (FFO) rose year over year in the first quarter of 2025, and it increased its full-year guidance. LTC Properties, meanwhile, expects 2025's adjusted FFO per share to be flat to slightly higher. However, it's diversifying its business approach to include senior housing operating properties (SHOP). (SHOP assets are owned and operated by the REIT, though it actually hires a third party to handle day-to-day management of the asset.) As it grows, this business should increasingly benefit from the growth in demand for senior housing as the U.S. population ages. The key takeaway here, however, is that, when faced with adversity, Omega and LTC Properties held firm in their commitment to shareholders. They adjusted as needed to keep paying. Medical Properties Trust, on the other hand, couldn't manage that feat. The past doesn't predict the future, of course, but the past is all we have to go on as investors. And since all three of these healthcare REITs have faced material adversity just recently, their strengths and weaknesses have been laid bare. While the worst might be over for Medical Properties Trust, most dividend investors should probably err on the side of caution with either Omega, which has a higher yield, or LTC Properties, which has a lower yield but a far more diversified business model. Before you buy stock in Medical Properties Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medical Properties Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead? was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store